Julie Parsons
Neurology with Special Qualifications in Child Neurology · Aurora, CONPI 1396820031
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Biogen at 30.0% of the total. Reporting peaked in 2024 at $39,134 and has fallen 55.6% since, to $17,387 in 2025. Among neurology with special qualifications in child neurology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $819.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$53K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$37K
- Genentech USA, Inc.$24K
- Ultragenyx Pharmaceutical Inc.$20K
- Sanofi$19K
- Novartis$16K
- plus $8K from 7 others
Across 115 payments — averaging $24,692 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$2.3M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$263K
- PTC Therapeutics, Inc.$172K
- Genentech, Inc.$39K
- Sarepta Therapeutics, Inc.$21K
- Biohaven Pharmaceutical Holding Company Ltd.$13K
What the payments were for
- Consulting fees$100,06256%
- Speaking & faculty fees$37,96821%
- Travel & lodging$13,1707%
- Food & beverage$4,0562%
- Education$22,63813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 36 | $53,410 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 117 | $37,269 |
| Genentech USA, Inc. | 18 | $23,539 |
| Ultragenyx Pharmaceutical Inc. | 9 | $20,173 |
| Sanofi | 6 | $19,445 |
| Novartis | 11 | $15,802 |
| Pfizer | 4 | $5,129 |
| PTC Therapeutics, Inc. | 1 | $1,600 |
| Sarepta Therapeutics, Inc. | 10 | $977 |
| Astellas Pharma US Inc | 2 | $384 |
| Genentech, Inc. | 1 | $141 |
| Catalyst Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$177,894 in reported general payments places this provider in the 95th percentile of 41 neurology with special qualifications in child neurology providers in Colorado.
See all neurology with special qualifications in child neurology providers in Colorado →
Other neurology with special qualifications in child neurology in Aurora
- Michele YangAurora$15K
- Timothy BenkeAurora$9K
- Ryan KammeyerAurora$4K
- Teri SchreinerAurora$3K
- Marcy YonkerAurora$3K
- Jessica LitwinAurora$2K
- Jennifer ArmstrongAurora$2K
- Abigail CollinsAurora$2K
- Jennifer JaskiewiczAurora$937
- Benjamin RossAurora$803
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.